title: [Multi-sequential arterial chemoembolization of advanced hepatocellular carcinomas: computerized tomography follow-up parameters for evaluating effectiveness of therapy].
abstract: OBJECTIVE
  An evaluation of clinical and computed tomography parameters for the transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC).
  
  
  METHODS
  Retro- and prospective analysis of 123 TACE procedures in 37 patients (mean age: 63.3 years).
  
  
  RESULTS
  Overall mean survival rate for all treated patients was 785 days with a mean value of 387 days. The 1 year survival rate was 62%. Quantitative tumor volumetry revealed a significant difference in survival rate with a mean value of 678 days for patients with a reduction of tumor volume between 0 and 50%, 976 days for a volume reduction of 51-100% and 277 days for an increase in tumor volume during therapy. Patients with a high lipiodol retention presented improved survival data (902 days) versus patients with a low lipiodol retention (513 days). Homogeneous retention of lipiodol was a positive factor on survival as compared to an inhomogenous form of retention.
  
  
  CONCLUSIONS
  In patients with a positive therapy response after TACE the prognosis can be improved by repeated embolization.
authors.affiliation: Institut für Diagnostische und Interventionelle Radiologie, Klinikum, J. W. v. Goethe-Universität, Frankfurt am Main. Vogl@em.uni.Frankfurt.de
authors.forename: T J
authors.initials: TJ
authors.lastname: Vogl
authors.forename: H
authors.initials: H
authors.lastname: Schroeder
authors.forename: M
authors.initials: M
authors.lastname: Trapp
authors.forename: R
authors.initials: R
authors.lastname: Straub
authors.forename: A
authors.initials: A
authors.lastname: Schuster
authors.forename: M
authors.initials: M
authors.lastname: Schuster
authors.forename: M
authors.initials: M
authors.lastname: Mack
authors.forename: F
authors.initials: F
authors.lastname: Souchon
authors.forename: P
authors.initials: P
authors.lastname: Neuhaus
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000098:blood supply / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D007459:Iodized Oil; D004317:Doxorubicin; D002945:Cisplatin